Buy Pt-141 10 mg + bacteriostatic water 3ml
€32.16
PT-141 (bremelanotide), 10 mg, with 3 mL bacteriostatic water, is a cyclic peptide format for analytical and in vitro laboratory research. Pharma Research .eu provides documented EU supply subject to lot-specific purity and identity verification.
Buy PT-141 (Bremelanotide), 10 mg + Bacteriostatic Water, 3 mL, for Advanced Laboratory Research in Europe
PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide used as a laboratory reagent in melanocortin-receptor pharmacology, peptide analytics and controlled in vitro investigations. The free-peptide composition is commonly reported as C₅₀H₆₈N₁₄O₁₀, with an average molecular mass of approximately 1,025.16 Da and CAS Registry Number 189691-06-3. Pharma Research .eu presents this 10 mg format with 3 mL of bacteriostatic water for qualified European laboratory teams requiring documented peptide materials.pubchem.ncbi.nlm.nih+2
Uncompromising Purity and Analytical Characterisation
PT-141 is a cyclic peptide with the commonly reported designation:
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
The cyclic structure includes a lactam bridge involving the Asp and Lys side chains. N-terminal acetylation, norleucine substitution, D-phenylalanine and cyclisation should be stated explicitly in the product specification because these structural features distinguish bremelanotide from unrelated linear melanocortin peptides.aminopeptides.co+1
For laboratory procurement, the appropriate target is ≥99.0% purity by RP-HPLC, subject to confirmation by the actual batch CoA. Commercial research specifications commonly pair HPLC purity with mass-spectrometric identity confirmation, but a catalogue percentage should not be treated as a substitute for reviewing the lot-specific chromatogram.americanpeptides+1
A complete certificate of analysis should include:
-
RP-HPLC purity, analytical method and chromatogram.
-
LC-MS, ESI-MS or high-resolution MS identity confirmation.
-
Sequence or structural designation, including cyclic configuration.
-
Molecular mass or principal molecular-ion assignment.
-
Appearance of the lyophilised product.
-
Residual solvent results from synthesis and purification.
-
Water or residual-moisture content, where tested.
-
Acetate or other counter-ion information, if the supplied material is a salt.
-
Heavy-metal or elemental-impurity results where included in the specification.
-
Lot number, manufacture date, retest date and storage requirements.
The free-peptide formula is generally listed as C₅₀H₆₈N₁₄O₁₀, with an exact mass of approximately 1,024.5243 Da and an average molecular mass near 1,025.16 g/mol. Bremelanotide acetate hydrate has a different reported composition and molecular mass, so the supplier must identify whether the 10 mg quantity refers to free bremelanotide, an acetate salt or a hydrated form.pubchem.ncbi.nlm.nih+1
The product is normally supplied as a white to off-white lyophilised powder. Visual inspection can identify gross discolouration, collapse or visible contamination, but it cannot confirm chemical identity or purity. Analytical release should combine visual inspection with RP-HPLC and mass-spectral testing.
High purity is important for reproducible receptor and signalling studies. Related cyclic-peptide impurities, incomplete cyclisation products, oxidation products or residual synthesis reagents can change chromatographic response, mass spectra and apparent assay potency. Non-characterised or lower-grade material may be unsuitable for quantitative method validation, publication-quality concentration–response analysis or inter-laboratory comparison.
The accompanying bacteriostatic water is a separate reagent. Its preservative composition, expiry date and quality documentation should be reviewed independently. Preservatives may influence LC-MS ionisation, chromatographic background, adsorption to plastics or cellular assay performance.
Principal Laboratory Applications and Research Methodologies
PT-141 is suitable for controlled analytical and in vitro research involving cyclic-peptide chemistry, melanocortin-receptor pharmacology and assay development. All work should be performed by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical laboratory.
Melanocortin-receptor assay development. Bremelanotide may be used as a defined ligand in receptor-binding, reporter-gene or second-messenger assays involving melanocortin receptor systems. A robust study should include vehicle controls, receptor-negative controls where relevant, concentration verification and an orthogonal analytical check of the test solution.
LC-MS and RP-HPLC characterisation. The material can support precursor-ion selection, product-ion optimisation, retention-time assignment and impurity profiling. Because PT-141 is cyclic and contains non-standard structural features, the analytical method should be validated for the intact peptide rather than relying on a generic linear-peptide method.
Peptide stability and degradation studies. Laboratories may assess changes under controlled temperature, light, pH, oxidative stress and freeze–thaw conditions. Stability-indicating methods should distinguish chemical degradation from adsorption, precipitation or loss during sample preparation.
Reference and system-suitability applications. A well-characterised batch may be used as a laboratory reference material for instrument checks, retention-time monitoring and assay development. Unless it has been formally certified under an applicable reference-material standard, it should not be described as a certified reference material.
The 10 mg nominal quantity corresponds to approximately 9.75 µmol using the reported free-peptide molecular mass of 1,025.16 g/mol. If the entire quantity were dissolved in 3 mL, the theoretical concentration would be approximately 3.33 mg/mL, or about 3.25 mM, before correction for purity, salt form, water content and final volume. This is a formulation calculation for laboratory planning, not a recommended biological-use protocol.
The 3 mL bacteriostatic-water component should be evaluated for compatibility with the chosen method. For LC-MS, a preservative-containing solution may require a solvent blank and matrix-effect study. For cell-based assays, preservative concentration, osmolality and sterility-related requirements should be assessed within the institutional protocol.
Compound Stability, Optimal Storage, and Safe Handling Protocols
PT-141 should remain sealed in its lyophilised state until required for a validated laboratory procedure. Research-product references commonly recommend low-temperature storage for the dry peptide and refrigerated storage for prepared solutions, but exact solution stability depends on concentration, solvent, container, pH and handling history. A generic “28-day” solution period should not be presented as a guaranteed stability claim without product-specific supporting data.realpeptides+1
Recommended controls include:
-
Store unopened lyophilised PT-141 at −20°C or according to the lot-specific CoA.
-
Keep the vial tightly closed, dry and protected from light.
-
Allow a sealed vial to reach room temperature before opening to minimise condensation.
-
Use low-binding containers when adsorption could affect recovery.
-
Prepare aliquots if repeated access would increase moisture exposure or contamination risk.
-
Store short-term aqueous solutions at 2–8°C only when supported by validation.
-
Use frozen aliquots for longer-term solution storage where stability data support that approach.
-
Avoid repeated freeze–thaw cycles.
-
Record solvent, concentration, preparation date, operator and storage history.
The cyclic structure may provide greater resistance to some proteolytic processes than a comparable linear peptide, but this does not eliminate the risk of chemical degradation, adsorption or physical instability. Temperature, pH, light, oxidation and container material should be treated as method variables.
Reconstitution should be performed using a validated laboratory procedure. Add bacteriostatic water gradually, allow the powder to hydrate, and mix gently to reduce foaming and surface adsorption. Do not assume that bacteriostatic water is interchangeable with sterile water, buffered saline or an organic solvent. Compatibility must be established for the intended analytical or cellular model.
Handling should follow the current SDS and institutional chemical-risk assessment. Appropriate controls generally include a certified fume hood or suitable local containment, nitrile gloves, safety goggles and a laboratory coat. Avoid generating aerosols and prevent contact with skin, eyes and laboratory surfaces. Manage contaminated materials through approved institutional chemical and laboratory-waste procedures.
Technical Specifications and Molecular Attributes
| Attribute | Specification |
|---|---|
| Product | PT-141 (bremelanotide), 10 mg, supplied with 3 mL bacteriostatic water |
| Common designation | Bremelanotide, PT-141 |
| Peptide structure | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Residue count | Cyclic heptapeptide |
| IUPAC name | Complex systematic naming should be confirmed against the supplier’s CoA; the structural sequence designation is preferred for procurement |
| CAS Registry Number | 189691-06-3 |
| Molecular formula, free peptide | C₅₀H₆₈N₁₄O₁₀ |
| Exact mass | Approximately 1,024.5243 Da |
| Average molecular mass | Approximately 1,025.16 g/mol |
| Physical state and colour | Lyophilised white to off-white powder |
| Solubility profile | Aqueous reconstitution may be feasible; solvent and buffer compatibility require assay-specific validation |
| Typical purity | Proposed target ≥99.0% by RP-HPLC; verify the lot-specific result |
| Identity testing | LC-MS, ESI-MS or high-resolution MS |
| Companion reagent | 3 mL bacteriostatic water |
| Long-term storage | Typically −20°C, sealed and protected from light and moisture |
The molecular formula, exact mass, average molecular mass, CAS number and cyclic sequence are supported by public chemistry and research references. If the supplied material is bremelanotide acetate hydrate rather than the free peptide, the formula and stated molecular mass must be updated to match the CoA.pubchem.ncbi.nlm.nih+2
Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents
Pharma Research .eu can position this PT-141 format as a documented European laboratory reagent for teams requiring a defined cyclic peptide and transparent analytical specifications. The product file should contain the batch-specific CoA, SDS, structural designation, purity result, identity data, storage instructions and documentation for the bacteriostatic-water component.
Any claim that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate identifying the issuing body, scope and validity. Claims regarding temperature-controlled or discreet logistics across EU member states should also be verified for the destination country, carrier route and applicable transport requirements.
A quality-focused supplier should be able to discuss:
-
Cyclic heptapeptide structure and lactam-bridge designation.
-
Free-peptide versus acetate or hydrate molecular mass.
-
RP-HPLC purity and LC-MS identity testing.
-
Residual solvents, moisture and elemental-impurity reporting.
-
Packaging configuration and container-closure integrity.
-
Compatibility of bacteriostatic water with analytical workflows.
-
Storage, transport and reconstitution documentation.
Pharma Research .eu should therefore be described as a potential European source for research-grade PT-141, with vendor-specific certification and logistics statements verified through current records. The material is intended strictly for controlled laboratory research and analytical use by qualified professionals under applicable institutional procedures.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.


Reviews
There are no reviews yet.